Table of Contents
Introduction
Prasugrel is a thienopyridine antiplatelet drug used to prevent thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). It inhibits platelet activation and aggregation by irreversibly blocking ADP receptors on platelets. Compared with clopidogrel, prasugrel produces more rapid and potent platelet inhibition.
Mechanism of Action (Step-wise)
- Prasugrel is administered as an inactive prodrug.
- It undergoes rapid hepatic activation by cytochrome P450 enzymes.
- The active metabolite irreversibly binds to platelet P2Y12 ADP receptors.
- P2Y12 receptors are Gi protein-coupled receptors located on platelets.
- Normally, ADP binding to P2Y12 receptors inhibits adenylate cyclase and decreases cAMP levels.
- Reduced cAMP promotes platelet activation and aggregation.
- Prasugrel blocks ADP-mediated activation of the P2Y12 receptor.
- This prevents activation of the GPIIb/IIIa receptor complex.
- Without active GPIIb/IIIa receptors, fibrinogen cannot effectively bind platelets together.
- Platelet aggregation is therefore inhibited.
- Since platelets cannot synthesize new receptors, inhibition persists for the platelet lifespan (7–10 days).
- The overall effect is prevention of arterial thrombosis and stent thrombosis.
A key exam point is that prasugrel irreversibly inhibits the platelet P2Y12 ADP receptor.
Pharmacokinetics
Prasugrel is administered orally and is rapidly absorbed. It is converted to its active metabolite in the liver. Compared with clopidogrel, prasugrel has more consistent activation and less variability due to genetic polymorphisms. Platelet inhibition begins rapidly after administration. Metabolites are excreted through urine and feces.
Clinical Uses
Prasugrel is used in acute coronary syndrome patients undergoing PCI to reduce the risk of myocardial infarction, stroke, and stent thrombosis. It is commonly used as part of dual antiplatelet therapy with aspirin.
Adverse Effects
The major adverse effect is bleeding, including serious and life-threatening hemorrhage. It should be used cautiously in elderly patients and those with low body weight. It is generally contraindicated in patients with a history of stroke or transient ischemic attack due to increased bleeding risk.
Comparative Analysis
| Feature | Prasugrel | Clopidogrel | Ticagrelor |
|---|---|---|---|
| Drug class | Thienopyridine | Thienopyridine | Cyclopentyltriazolopyrimidine |
| P2Y12 blockade | Irreversible | Irreversible | Reversible |
| Activation | Prodrug | Prodrug | Active drug |
| Onset | Rapid | Slower | Rapid |
| CYP2C19 dependence | Less | Significant | Minimal |
| Bleeding risk | Higher | Moderate | Moderate–high |
Prasugrel differs from clopidogrel by producing more potent and consistent platelet inhibition with less dependence on CYP2C19 polymorphism. Compared to ticagrelor, prasugrel binds irreversibly and requires metabolic activation.
MCQs
- Prasugrel blocks which platelet receptor?
a) GPIIb/IIIa
b) P2Y12
c) H1 receptor
d) β1 receptor
Answer: b) P2Y12
- The P2Y12 receptor is normally activated by:
a) ATP
b) ADP
c) Calcium
d) Serotonin
Answer: b) ADP
- Prasugrel is classified as a:
a) Anticoagulant
b) Antiplatelet drug
c) Thrombolytic
d) Vasodilator
Answer: b) Antiplatelet drug
- Prasugrel is administered as a:
a) Direct active drug
b) Prodrug
c) Hormone
d) Steroid
Answer: b) Prodrug
- Prasugrel inhibits platelet aggregation by preventing activation of:
a) Sodium channels
b) GPIIb/IIIa receptors
c) Calcium pumps
d) Histamine receptors
Answer: b) GPIIb/IIIa receptors
- Prasugrel inhibition of platelets is:
a) Reversible
b) Irreversible
c) Competitive only
d) Temporary for minutes
Answer: b) Irreversible
- Prasugrel is mainly used in:
a) Asthma
b) Acute coronary syndrome
c) Diabetes
d) Epilepsy
Answer: b) Acute coronary syndrome
- The major adverse effect is:
a) Hyperglycemia
b) Bleeding
c) Bradycardia
d) Hypercalcemia
Answer: b) Bleeding
- Prasugrel is often combined with:
a) Metformin
b) Aspirin
c) Omeprazole
d) Digoxin
Answer: b) Aspirin
- Compared with clopidogrel, prasugrel has:
a) Slower onset
b) More potent platelet inhibition
c) Less bleeding risk
d) No CYP metabolism
Answer: b) More potent platelet inhibition
- Prasugrel is contraindicated in patients with history of:
a) Asthma
b) Stroke or TIA
c) GERD
d) Hypothyroidism
Answer: b) Stroke or TIA
- Platelet inhibition lasts for:
a) A few minutes
b) Platelet lifespan
c) One hour only
d) Until renal excretion only
Answer: b) Platelet lifespan
FAQs
What is the mechanism of action of prasugrel?
Prasugrel irreversibly blocks platelet P2Y12 ADP receptors, preventing platelet aggregation.
Why is prasugrel considered more potent than clopidogrel?
Because it undergoes more efficient activation and produces stronger platelet inhibition.
What is the major side effect of prasugrel?
Bleeding.
Why is prasugrel used after PCI?
To prevent stent thrombosis and recurrent cardiovascular events.
Is prasugrel reversible or irreversible?
It irreversibly inhibits platelet P2Y12 receptors.
Why should prasugrel be avoided in patients with prior stroke?
Because of increased risk of serious bleeding.
References
Goodman & Gilman’s The Pharmacological Basis of Therapeutics – Antiplatelet Drugs
https://accessmedicine.mhmedical.com/book.aspx?bookid=3191
Katzung: Basic and Clinical Pharmacology – Drugs Affecting Coagulation
https://accessmedicine.mhmedical.com/content.aspx?bookid=3382
Tripathi: Essentials of Medical Pharmacology – Antiplatelet Drugs
https://www.jaypeedigital.com
Harrison’s Principles of Internal Medicine – Acute Coronary Syndromes
https://accessmedicine.mhmedical.com
